同和药业(300636) - 2024 Q3 - 季度财报

Revenue and Profitability - Revenue for Q3 2024 increased by 5.61% year-on-year, totaling CNY 569,933,408.38[2] - Net profit attributable to shareholders rose by 21.10% to CNY 95,736,461.60, with a year-to-date increase of 21.72%[2] - Basic earnings per share increased by 19.54% to CNY 0.2280, with diluted earnings per share showing a similar increase of 18.63%[2] - Net profit for the third quarter was ¥95,736,461.60, representing a 21.76% increase from ¥78,653,167.86 in the previous year[16] - Earnings per share increased to ¥0.2280, compared to ¥0.2143 in the same quarter last year[16] Cash Flow - Cash flow from operating activities reached CNY 162,163,824.25, reflecting a significant increase of 53.38%[2] - The net cash flow from operating activities increased by 53.38% to ¥162,163,824.25 compared to ¥105,729,138.58 in the same period last year, primarily due to a decrease in cash paid for goods and services[8] - Total cash inflow from operating activities is ¥521,186,224.17, down 6.5% from ¥557,523,692.04 in the previous period[17] - Cash outflow from operating activities decreased to ¥359,022,399.92, a reduction of 20.5% from ¥451,794,553.46 in the previous period[17] Assets and Liabilities - Total assets as of the end of Q3 2024 amounted to CNY 3,221,439,738.99, representing a 2.29% increase from the previous year[2] - Total assets amounted to ¥3,295,084,846.88, up from ¥3,221,439,738.99 at the end of the previous year[14] - Total liabilities decreased to ¥985,719,380.69 from ¥994,990,614.72 year-on-year[14] - The company's equity attributable to shareholders reached ¥2,309,365,466.19, an increase from ¥2,226,449,124.27 in the previous year[14] Accounts Receivable and Inventory - The company reported a 50.19% increase in accounts receivable, totaling CNY 106,289,452.65, primarily due to unsettled payments[5] - Accounts receivable increased to ¥106,289,452.65 from ¥70,771,939.06 in the previous period[12] - Inventory rose to ¥561,229,478.14 from ¥523,416,724.31, indicating a growth in stock levels[12] Borrowings and Financial Expenses - Long-term borrowings increased by 59.40% to CNY 398,500,000.00, attributed to new long-term loans taken during the period[6] - The company reported a decrease in short-term borrowings to ¥329,428,036.67 from ¥429,312,470.41 year-on-year[15] - Financial expenses showed a significant change, with a net income of -¥13,031,592.68 compared to -¥4,044,746.02 in the previous year[15] Tax and Investment Income - Tax and additional charges rose by 91.99% year-on-year, reaching CNY 5,380,972.73, mainly due to increased property tax[7] - Investment income surged by 100% to CNY 606,704.78, driven by higher financial management returns[7] Cash and Cash Equivalents - The company's cash and cash equivalents decreased significantly from ¥512,753,422.59 at the beginning of the period to ¥132,148,876.62 at the end of the period[12] - The ending balance of cash and cash equivalents is ¥116,345,276.10, down from ¥367,231,637.75 in the previous period[18] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,352[9] - The largest shareholder, Mr. Pang Zhengwei, holds 15.66% of the shares, totaling 66,009,954 shares, with 49,507,465 shares under pledge[9] Research and Development - Research and development expenses were ¥39,204,527.63, down from ¥47,477,333.47 in the same period last year[15] Audit Status - The company has not undergone an audit for the third quarter report[19]